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Abstract: Obesity is an excessive adipose tissue accumulation that may have detrimental effects
on health. Particularly, childhood obesity has become one of the main public health problems
in the 21st century, since its prevalence has widely increased in recent years. Childhood obesity
is intimately related to the development of several comorbidities such as nonalcoholic fatty liver
disease, dyslipidemia, type 2 diabetes mellitus, non-congenital cardiovascular disease, chronic
inflammation and anemia, among others. Within this tangled interplay between these comorbidities
and associated pathological conditions, obesity has been closely linked to important perturbations in
iron metabolism. Iron is the second most abundant metal on Earth, but its bioavailability is hampered
by its ability to form highly insoluble oxides, with iron deficiency being the most common nutritional
disorder. Although every living organism requires iron, it may also cause toxic oxygen damage by
generating oxygen free radicals through the Fenton reaction. Thus, iron homeostasis and metabolism
must be tightly regulated in humans at every level (i.e., absorption, storage, transport, recycling).
Dysregulation of any step involved in iron metabolism may lead to iron deficiencies and, eventually,
to the anemic state related to obesity. In this review article, we summarize the existent evidence on
the role of the most recently described components of iron metabolism and their alterations in obesity.
Keywords: anemia; childhood obesity; iron; metabolic syndrome; metabolism; obesity
1. Childhood Obesity
Chronic diseases, also known as non-communicable diseases (NCDs), are the result of a
combination of behavioral, environmental, genetic and physiological factors, being responsible
for the 75% of deaths in low- and middle-income countries. Among them, obesity, along with cancer,
cardiovascular diseases and diabetes, is one of the main NCDs worldwide [1]. Obesity is defined as an
excessive fat accumulation that may have detrimental effects on health. Particularly, childhood obesity
has become one of the main public health problems in the 21st century, since its prevalence has widely
increased in recent years. In 2016, over 41 million children under five years of age were overweight or
obese around the world. In developing countries, the prevalence of childhood obesity and overweight
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children has increased up to 30% of preschool children. If the actual growth rate is sustained, 70 million
children will be obese or overweight in 2025. Obese children are more likely to become obese adults,
with higher probabilities of suffering other NCDs like diabetes or cardiovascular diseases. Thus,
childhood obesity prevention and treatment strategies need to be given primary importance [2,3].
2. Metabolic Syndrome
Over 35% of obese children under 10 years of age present at least one cardiovascular risk factor
or metabolic disturbance (e.g., arterial hypertension, dyslipidemia, disturbed glucose tolerance),
with insulin resistance (IR) being the most common and the earliest to appear. It is already found
in patients under five years old [4]. This situation, known as metabolic syndrome (MetS), is a
group of cardiovascular risk factors associated with IR of which the main clinical alterations are
cellular dysfunction, high fasting triglycerides and glucose, hypertension, low high density lipoprotein
cholesterol (HDL-col), systemic inflammation and visceral obesity. It was Gerald Reaven who first
named this cluster of risk factors “insulin resistance syndrome” (IRS) after discovering an inverse
relationship between MetS and insulin sensitivity, as insulin resistance seems to be the main determinant
in the development of this syndrome [5]. In obesity, an increased amount of visceral adipocytes is
translated into increased chemo-attractants, meaning higher macrophage infiltration and cytokine
release, contributing to systemic inflammation. Likewise, adipocyte dysfunction is accompanied
by reduced adiponectin production and higher release of fatty acids. Released free fatty acids may
in turn alter the mitochondrial function in peripheral tissues and consequently increase oxidative
stress (OS), which lowers the insulin sensitivity of those tissues. Accordingly, insulin production
requirements become greater, and the acquired resistance raises circulating glucose levels, increasing
the risk of developing type 2 diabetes mellitus (T2DM). There is not yet an international consensus in the
definition of childhood MetS; however, it is widely accepted that four components have to be included,
namely abdominal obesity, arterial hypertension, dyslipidemia and altered glucose metabolism, so
that MetS is diagnosed when abdominal obesity is accompanied by at least two of these other clinical
alterations [6–9].
3. Obesity Comorbidities
As the prevalence and severity of obesity increases at young ages, it is common to find obese
children with elevated transaminases and nonalcoholic fatty liver disease (NAFLD), which has become
the major hepatic disease in children. Thus, NAFLD and MetS are strongly inter-related, and IR is
thought to drive the appearance of this “hepatic manifestation of MetS” [6–9]. Fat deposition in the
liver (distinctive for NAFLD) is a consequence of obesity in all ages [10,11], and it may progress to more
serious liver dysfunction. Renal pathologies such as hyperfiltration and microalbuminuria may be also
associated with obesity [12]. Childhood obesity-associated dyslipidemia increases the risk of suffering
it in adulthood [13], and childhood type 2 diabetes mellitus prevalence also increases with obesity [14].
Vitamin D and iron deficiencies have been found to be increased in overweight and obese children,
proving that obesity can be considered a quantitative and qualitative form of malnutrition [15,16].
Finally, anxiety, depression, stress and other psychological conditions have all been reported to be
more common in obese children and adolescents [10,17].
Childhood obesity is also strongly associated with hypertension, which increases the risk of
vascular endothelial dysfunction in adult life [18]. Both leptin and adiponectin, adipocyte-secreted
cytokines, have a direct effect on endothelial function along with chemerin, a newly described adipokine
involved in the obesity-inflammation cycle; its levels have been described to be higher in obesity [19–21].
Non-congenital cardiovascular disease (CVD) is becoming more prevalent in children along with the
rise in childhood obesity [22]. Body mass index (BMI), IR and cardiovascular parameters such as left
ventricular (LV) mass seem to have a positive relationship in children with obesity [23–25]. It is also
known that atherosclerosis may start already in children under 10 years of age. In this sense, metabolic
parameters in children such as cholesterol, blood pressure, triglyceride concentration or BMI, all them
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involved in higher risk for cardiovascular disease, have been found to be tightly correlated with adult
levels [26].
Obese patients have higher plasma concentrations of all pro-thrombotic factors when compared
to non-obese controls [27], possibly due to the hyperinsulinemic state [28]. Obese patients have
higher plasma concentrations of PAI-1 (plasminogen activator inhibitor-1), the main inhibitor of
plasminogen activation, which is synthetized in adipose tissue and of which the levels decrease
after weight reduction [29]. Obese women are also characterized by higher plasma concentrations
of anti-thrombotic factors [27], which may be interpreted as a response to the rise in pro-thrombotic
factors. However, even when the anti-thrombotic factors’ concentration is higher, their activity is
decreased in obese subjects (i.e., t-PA activity) [28]. Obesity is also characterized by resistance to
activated protein C, another antithrombotic protein [30]. In diseases like type 2 diabetes, amelioration
of insulin resistance and reduction of insulin levels recover the fibrinolytic function [31]. Insulin acts by
inhibiting platelet-collagen interactions, reducing aggregation to several agonists [32]. In obese subjects,
insulin loses its inhibitory capacity over platelet thrombus formation, facilitating the development of
atherothrombotic diseases in IR [32,33].
4. Obesity, Inflammation and Oxidative Stress
Obesity is characterized by a low-grade systemic chronic inflammatory state. This chronic
inflammation courses with changes in adipose tissue and inflammatory cells (like neutrophils,
monocytes, lymphocytes and tissue-specific macrophages) and tissue destruction, leading to an
increased level of plasma inflammatory markers and inflammatory cells in circulation [34].
Various mechanisms are involved in this chronic inflammatory state. Lysosomal defective function
has been described in obese mice. This dysfunction is accompanied by an induction in the expression
of CD36, and CD36 knockout mice are protected from this lysosomal impairment. CD36 mediates
the activation of inositol, which in turn increases the calcium influx into the lysosome, leading to
its functional impairment [35]. As reviewed by Pessentheiner et al., the role of proteoglycans in
the development of metabolic disturbances and low-grade inflammation has acquired increasing
relevance. These glycoproteins located in the cell surface interact with a great number of proteins
involved in metabolic homeostasis and inflammation [36]. Obesity is also able to cause lymphatic
impairment, as inflammatory cells surround the lymphatic vessels and alter anion exchange and
lymphatic endothelial cells. This may contribute to low-grade tissue inflammation and the accumulation
of inflammatory cytokines [37]. Obesity also mediates changes in bone-marrow, where immune cells
are originated. This stem cell differentiation impairment affects systemic inflammatory pathways [38].
In the adipose tissue, an excessive caloric uptake by adipocytes induces the release of numerous
inflammatory mediators, such as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6). These in
turn stimulate C-reactive protein (CRP) release. On the other hand, adiponectin secretion is reduced,
and all these processes result in a pro-inflammatory environment [39]. In addition to the raise in
cytokine production, obesity is characterized by increased adhesion molecule levels, which, along with
the mentioned cytokines, stimulate tissue-specific macrophage recruitment. Such local inflammation
eventually induces IR [40]. Based on the analytical changes in the chemokine, adipokine and cytokine
profiles of obese children, Rivera et al. developed a diagnostic tool for IR, rendering a sensitivity and
specificity of 93.2%, including levels of leptin, triglyceride:HDL-col ratio, insulin-like growth factor-I
(IGF-I), TNFα, monocyte chemoattract protein 1 (MCP1) and pro-fibrotic platelet-derived growth factor
(PDGF-BB) [41]. In obese children, higher obesity severity is associated with higher free fatty acid
(FFA) levels. IL-6 levels were found to be related to adipose IR [42]. In childhood obesity, adipokines
like leptin, IL-6, TNFα and progranulin are increased [43,44]. In addition, leukocyte, lymphocyte,
erythrocyte, platelet, CRP and transaminase levels have been found to be higher in obese/overweight
children when compared with a control group as a sign of a pro-inflammatory status [45].
OS and inflammatory milieu are known to be interrelated. Whether OS leads to inflammation or if
it is the proinflammatory state that leads to a pro-oxidant environment remains controversial. OS seems
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to play a role in the development of chronic inflammatory diseases. Inflammatory stimuli lead to
peroxiredoxin 2 (PRDX2) release. PRDX2, an enzyme with redox capacity acting as an inflammatory
mediator, induces macrophages to release TNFα [46]. On the other hand, inflammatory cells release
several reactive species at the site of inflammation, leading to OS. Additionally, reactive species may
also be released by nonphagocytic cells in response to cytokines. Those reactive species can in turn
activate signaling cascades that stimulate proinflammatory gene expression. In this line, hydrogen
peroxide (H2O2) may lead to inflammation through NF-κB activation. OS is also involved in the
activation of NOD-like receptor protein 3 (NLRP3) inflammasome, a complex that triggers innate
immune defenses by maturation of proinflammatory cytokines [47].
OS also plays a role in the development of MetS. Levels of HDL-col, well known for its antioxidant
and anti-inflammatory actions, are lower in obese adults and children with MetS. Recent studies
also link gamma-glutamyl transferase (GGT) to MetS, given its relation to glutathione metabolism
and thus antioxidant defense [48]. Our group previously described marked differences in oxidative
stress biomarkers and antioxidant response between obese children and controls, and even between
metabolically healthy and metabolically unhealthy obese children. Obese children with insulin
resistance presented higher levels of thiobarbituric acid reactive substances (TBARS) as a lipid
peroxidation marker after an oral glucose tolerance test (OGTT) when compared to controls and obese
children without insulin resistance. They also presented an impaired capacity to activate catalase
activity after an OGTT [49]. Along with these results, Kilic et al. found that obese children presented an
increase in both total oxidant and antioxidant status [50]. Isoprostane (lipid peroxidation marker) is also
higher in obese children and is related to urinary H2O2, high-sensitivity CRP, HOMA-IR (HOmeostatic
Model Assessment for Insulin Resistance) and triglycerides [51]. In prepubescent children, total
antioxidant capacity is inversely related to the percentage of fat mass and waist circumference [52].
Of note, lower levels of serum antioxidants of nutritional origin, (such as retinol, β-carotene and
vitamin E) are related to increased metabolic alterations in obese adolescents [53].
5. Childhood Obesity and Anemia
In 1962, Wenzel et al. were the first to find lower serum iron levels in obese patients when
compared with a control group [54]. In the past decades, numerous theories have been raised to
attempt to give an explanation of this fact, such as dietary deficiencies of iron (which has not been
reproduced later [55]), higher iron requirements due to a higher blood volume, or lower myoglobin in
the muscle due to the absence of physical activity [56]. However, in the past few years, the chronic
inflammatory state associated with obesity and the role of hepcidin have gained great relevance.
The main physiological characteristic of obesity is the increased number of adipocytes and their
greater size, but adipocytes also suffer other functional changes of great importance. In obesity,
as mentioned above, there is constant macrophage infiltration into adipose tissue and changes in
the local production of pro-inflammatory cytokines such as interleukin 1 and 6 (IL-1, IL-6) and
tumor necrosis factor α (TNFα) [57]. These changes in cytokine production could lead to impaired
erythropoietin production and altered response of erythroid precursors, a recognized mechanism of
anemia associated with chronic diseases [58].
Zhao et al. found lower serum iron concentrations and transferrin saturation in a group of
obese/overweight participants when compared to a control group [59]. Manios et al. found ferritin
levels to be higher in a group of obese school children aged between 9 and 13 when compared with a
control group, together with a negative correlation between transferrin saturation and adiposity [60].
Del Giudice et al. proved iron levels and transferrin saturation to be lower in obese children, whereas
hepcidin levels where higher in the obese group when compared with control participants [61]. A study
performed in 2018 found higher levels of C reactive protein (CRP), hepcidin, leucocytes, platelets,
leptin and total iron binding capacity (TIBC) in an obese population when compared with controls.
On the other hand, mean corpuscular volume (MCV), adiponectin levels and transferrin saturation
were lower in the obese group. They did not find any differences in hemoglobin, serum ferritin,
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iron and IL-6 [62]. However, a third of MetS patients suffer from hyperferritinemia with a normal
transferrin saturation. This correlation is called “dysmetabolic iron overload syndrome” (DIOS) [63].
Bertinato et al. found diet-induced obese rats to have lower mean corpuscular hemoglobin (MCH) and
liver iron concentrations [64]. As an indirect marker of bone marrow turnover and anemic state our
group found volumetric dispersion of erythrocytes to be higher in a group of prepubescent children
(Figure 1). Supporting our finding, Fujita et al. found red cell distribution width (RDW) to be higher in
obese and overweight adolescents when compared with a control group [65]. With a group of 110
children aged between 6 and 16 years (50 obese and 60 healthy children), Doğan et al. also found that
RDW and ferritin levels were significantly higher in obese children when compared to the control
group, while having lower serum iron and transferrin saturation levels [66].
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6. Iron Metabolism
Iron is the second most abundant metal on Earth, being crucial for almost every living organism.
However, its ability to form highly insoluble oxides when it is in contact with oxygen reduces its
bioavailability. Moreover, according to the World Health Organization (WHO), iron deficiency is
the most common nutritional disorder in the world [67]. To counteract this, humans and all living
organisms have developed efficient mechanisms to capture iron in useful states [68]. Humans need
iron as a cofactor for hemoproteins (catalase (CAT), cytochromes, hemoglobin or myoglobin) and
other non-heme proteins involved in cell proliferation and differentiation, DNA synthesis or drug
metabolism [69]. On the other hand, iron can also lead to the formation of toxic oxygen free radicals
(hydroxyl radical) through the Fenton reaction. Thus, iron metabolism needs to be tightly regulated
at cellular and organism levels. Iron regulation is strictly dependent on redox state (Fe2+/Fe3+); to
be absorbed, and when serving as a cofactor, it needs to be in the reduced state (Fe2+), but when
transported by transferrin or stored as ferritin, it is in its oxidized form (Fe3+). At the cellular level, iron
regulation is accomplished by iron importers, iron storage proteins or iron efflux pumps among others,
which allow the transport of iron to its sites of utilization, minimizing its availability for reactive oxygen
species (ROS) generation. Once in the cell, iron is submitted to compartmentalization: mitochondria
for heme biosynthesis, iron-containing and iron regulatory proteins in the cytoplasm, etc. At the whole
organism level, iron metabolism is regulated at different levels: absorption (by enterocytes in the
duodenum), utilization (mainly erythrocyte production in bone marrow), storage (liver) and recycling
(spleen and reticuloendothelial system, RES) [70]. We summarize physiological iron metabolism in
Figure 2 and proceed to detail every step of it.
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Figure 2. Physiology of Iron Metabolism. Iron ingested from the diet (A), is reduced from Fe3+ to Fe2+ in the stomach (B). In the duodenum, enterocytes transport
Fe2+, heme groups and ferritin across the microvillus membrane (C). Fe2+ is transported by ferroportin across the basolateral membrane into the portal system and
must be oxidized to Fe3+ for binding to transferrin and other molecules with high affinity for Fe3+ to be transported to the liver. Transferrin-bound iron is necessary for
cells expressing transferrin receptors for uptake of iron, mainly for production of heme proteins (D). Transferrin-bound iron is taken up by myocytes, where Fe3+ is
oxidized again to Fe2+ in order to be incorporated into myoglobin (E), hepatocytes being the main ferritin store (F), and by proerythroblasts for synthesis of hemoglobin
(G). When mature erythrocytes die, macrophages liberate Fe2+ from hemoglobin, which is oxidized again to recirculate bound to transferrin (H). Finally, 1–2 mg iron is
lost per day from the organism by desquamation, bleeding and other mechanisms (I). Vit. C: vitamin C; DMT1: divalent metal transporter 1; ZIP 14/8: Zrt–Irt-like
protein 14 and 8; DcytB: duodenal cytochrome B; STEAP 2: six-transmembrane epithelial antigen of the prostate 2; HCP1: heme carrier protein 1; AP2: adaptor-related
2 protein; PCBP: poly (rC) binding protein; LIP: labile iron pool; HO1: heme oxygenase 1; FPN1: ferroportin 1; HEPH: hephaestin; CP: ceruloplasmin; FLVCR: feline
leukemia virus subgroup C; BCRP: breast cancer-resistant protein; Tf: transferrin; TfR: transferrin receptor; CAT: catalase; Scara 5: scavenger receptor class A, member
5; TIM2: T-cell immunoglobulin and mucin domain-containing protein 2; STEAP 3: six-transmembrane epithelial antigen of the prostate 3; NCOA4: nuclear receptor
coactivator 4; BFU-e: burst forming unit-erythroid; CFU-e: colony forming unit-erythroid; EPO: erythropoietin; Hb: hemoglobin; Hp: haptoglobin; CD163: cluster of
differentiation 163; CD91/LRP: cluster of differentiation/ low-density lipoprotein receptor related protein; HRG: heme responsive gene.
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6.1. Iron Absorption
In humans, the absorbed iron is limited to approximately 10% of the total iron consumed through
the diet. This absorption takes place mainly in the duodenum by the action of enterocytes, which
absorb heme-bound iron via the heme carrier protein 1 transporter (HCP1), also known as PCFT/HCP1,
since this protein is a proton-coupled folate transporter (PCFT) [69,71]. In the enterocyte, heme can be
degraded or absorbed into the circulation. Heme-oxygenase (HO-1), in association with cytochrome
P450 (CYP450), is the enzyme responsible for the degradation of absorbed heme groups in the enterocyte
to release free iron (Fe2+), which will join the labile iron pool (LIP), and generate carbon monoxide and
biliverdin, subsequently converted into bilirubin by biliverdin reductase [72,73]. Alternatively, intact
heme absorption into the circulation is carried out by two transporters in the basolateral membrane of
the enterocyte: the breast cancer-resistant protein (BCRP) and the feline leukaemia virus subgroup C
(FLVCR) [74].
The most common non-heme iron species found in food is the ferric form (Fe3+) bound to citrate
(or acetate), a highly insoluble and non-easily absorbable form. To accomplish its absorption, ferric
iron is reduced to ferrous iron (Fe2+) by means of the low pH in the stomach or the presence of other
metabolites like dietary ascorbic acid (vitamin C). In addition to these two, the enterocyte has its own
mechanisms to reduce Fe3+ to allow its absorption. Indeed, at the enterocytes’ apical membrane, facing
the gut lumen, there are two proteins capable of the enzymatic reduction of ferric iron using electrons
from the oxidation of ascorbic acid (known as ferrireductases): the duodenal cytochrome b (Dcytb)
and the six-transmembrane epithelial antigen of the prostate 2 (STEAP2). Once reduced, divalent
iron can be transported into the enterocytes through the divalent metal transporter 1 (DMT1, also
called Nramp2, SLC11A2 and DCT1) or the zinc transporter Zrt–Irt-like protein 14 and 8 (ZIP 14/8).
Protons, needed as the driving force for iron transport, are supplied by a sodium/hydrogen exchanger
(NHE3) [75–77].
Finally, enterocytes are also able to absorb dietary ferritin by an endocytosis mechanism related to
the adaptor-related 2 protein complex (AP2) [78].
6.2. Iron Storage
Once in the enterocyte, ferrous iron may either be stored or sent to the circulation to be transported
by the liver-delivered protein transferrin (Tf). In the enterocyte, ferrous iron becomes part of the
labile iron pool (LIP). The rest is transported to form different cellular stores in the form of ferritin.
The molecule responsible for iron incorporation into ferritin is the poly (rC) binding protein 1 (PCBP)
chaperone. In fact, PCBP chaperones also transfer ferrous iron to other proteins that are able to bind
iron as a cofactor, such as myoglobin, CAT and cytochromes [77]. Ferritin is composed of two different
subunits known as heavy (H) and light (L) chains, which form a space with a diameter of 8 nm, in which
4500 iron ions (Fe3+) can be stored. To that end, H-chains have ferroxidase activity for the oxidation of
ferrous to ferric iron, and acidic residues contained in L-chains are crucial for the nucleation of the
oxidized ferric iron within the formed core [46]. Ferritin can also be found in plasma, and two different
mechanisms have been described for ferritin uptake by the cell, one mediated by an H-ferritin receptor
called TIM2 (T-cell immunoglobulin and mucin domain-containing protein 2) and the second one
mediated by the L-ferritin receptor Scara5 (scavenger receptor class A, member 5) [15,79].
6.3. Iron Transport and Utilization
Ferroportin 1 (FPN1, also called MTP1, IREG1 and SLC40A1) regulates the transport of ferrous iron
across the enterocyte’s basolateral membrane into the blood stream [80]. FPN1 is a cytoplasmic protein
that needs to be translocated to the cell membrane by mon1a [81]. Ferrous iron now must be oxidized
back to the ferric form to be transported by transferrin (Tf). To accomplish this, hephaestin (HEPH), a
multi-copper ferroxidase enzyme in the enterocyte’s basolateral membrane coupled to FPN1, catalyzes
the oxidation of ferrous iron to ferric iron. Ceruloplasmin (CP) also acts as a ferroxidase enzyme
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in some tissues. In fact, deletion of HEPH and CP genes leads to systemic iron deficiency [82,83].
Once oxidized, Fe3+ binds to Tf, which has two iron-binding sites. When Tf is iron-free it is called
Apo-Tf, and if Tf is saturated with two ferric iron atoms it is called Holo-Tf. Transferrin receptor (TfR)
affinity for Tf depends on this saturation state, being much greater for Holo-Tf than for Apo-Tf [84].
Ferritin degradation has been recently proposed as an alternative mechanism for iron release. Such
degradation takes place by lysosome and proteasome-mediated mechanisms. In this sense, nuclear
receptor coactivator 4 (NCOA4) seems to act as the receptor binding ferritin and delivering it to
lysosomes [85].
TfR1, expressed in almost every nucleated cell, and in a lower proportion in DMT1 and ZIP14, is
implicated in transferrin-bound ferric iron (TBI) absorption [77]. As mentioned above, TfR1 has a high
affinity for TBI. Binding of hemochromatosis protein (HFE) to TfR1 decreases the affinity between TfR1
and holo-Tf. Subsequently, endocytosis of the TBI-TfR1 takes place and clathrin-coated endosomes are
formed. Once clathrin is removed, ATP-dependent proton pumps acidify the endosome matrix and,
inducing conformational changes in Tf and TfR1, dissociate ferric iron from the complex. However, Tf
remains bound to its receptor until it is again transferred to the cell membrane by the trafficking protein
Sec15l1. Once outside the cell, external pH leads to the release of Apo-Tf. Dissociated iron may then be
reduced to Fe2+ by another ferroreductase, the six-transmembrane epithelial antigen of the prostate 3
(STEAP3). Finally, ferrous iron may exit the endosome via DMT1 to be used/stored by the cell [84,86].
As well as TfR1, there is another isoform of the transferrin receptor: TfR2. TfR2 is mainly
expressed in hepatocytes and erythroid precursors, and its main function seems to be as an iron
sensor, since holo-Tf upregulates its expression. In erythroid precursors, TfR2 plays a relevant role
in erythropoiesis by biding to the erythropoietin receptor and facilitating ferric iron transport from
lysosomes to mitochondria safely, both in erythroblasts and dopaminergic neurons [86]. Moreover,
there is another member of the Tf family first described in human milk and named lactoferrin (hLf),
with lower affinity to ferric iron than transferrin. Lactoferrin is thought to be involved in the defense
against inflammation processes [87].
Besides the transferrin, there is a transferrin-independent iron influx/efflux system: the neutrophil
gelatinase-associated lipocalin (NGAL, LCN2)–24p3R/megalin–siderophore axis. NGAL, part of the
lipocalin family, binds to siderophores, which are high-affinity iron chelators. The complex formed by
NGAL, ferric iron and a siderophore binds to the cell-surface receptor 24p3R (also known as SLC22A17)
or megalin and is susceptible to receptor-mediated endocytosis. This 24p3R/megalin cell-surface
receptor also mediates the uptake of apo-NGAL, so it can bind ferric iron within the cell and make it
exportable [88,89].
In mitochondria, after mitoferrin-mediated ferrous iron transport through the inner membrane,
frataxin (FXN) seems to be responsible for delivering iron to a ferrochelatase involved in the final
step of heme production, the insertion of ferrous iron into protoporphyrin IX (PPIX). By the inhibition
of delta aminolevulinate synthase (ALAS), a catalyst of the first step in porphyrin ring production,
regulated by hemin (the oxidized form of heme), or induction of HO1, heme serves as a regulator of its
own homeostasis. Iron is also used in the synthesis of iron-sulfur clusters (ISCs) for later incorporation
into electron transfer proteins. FXN is also one of the components of a multimeric protein core complex
named ISCU, involved in the production of those ISCs. The formed cluster can either be used in the
mitochondria or transported to the cytoplasm through the ABC transporter ABCB7. Recently, FXN has
been described to act as a main regulator of ferroptosis, (a recently described novel form of cell death),
by regulating mitochondrial function and iron homeostasis [70,90–93].
6.4. Iron Recycling
Humans lack an active system of iron secretion, but about 1–2 mg of iron is lost by means of
skin desquamation, bleeding, infestations, etc. The RES is responsible of the recycling of about 25 mg
of iron every day, pointing to the great relevance that iron recycling displays in iron homeostasis in
humans [94].
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To maintain the required rate of erythropoiesis (200 billion new erythrocytes every day) and
the subsequent heme synthesis, 24 mg of iron are needed per day. To cover these iron requirements,
macrophages are deeply involved in iron recycling in various ways. Macrophages present different
iron uptake mechanisms such as the usual import of transferrin-bound or non-transferrin-bound iron,
ferrous iron uptake via natural resistance-associated macrophage protein 1 (NRAMP1) or Dmt1 (also
known as NRAMP2, as mentioned above) or senescent erythrocyte phagocytosis [95,96]. To accomplish
phagocytosis, macrophages recognize some ageing signals exhibited by senescent erythrocytes, such
as an increase of membrane phosphatidylserine and a decrease in membrane flexibility or the antigen
CD47 [97]. Erythrocytes are then incorporated into the denominated phagolysosomes, where they
are degraded by ROS and hydrolytic enzymes until heme release. Released heme is degraded by the
above-mentioned HO-1 into biliverdin, carbon monoxide and ferrous iron. Iron transport within the
macrophage is performed in three stages. First, heme is transported to the cytosol across phagosome
membrane by heme responsive gene 1 (HRG1). After its degradation, ferrous iron is transported
through the cytoplasm by PCBP1, and is finally delivered to FPN1 to be exported and reduced by CP
in circulation, making possible its transport through the organism via Tf [76,95,96].
With hemolysis, hemoglobin is released into the circulation. Hemoglobin in plasma is bound
by haptoglobin, and the hemoglobin-haptoglobin complex is recognized by the CD163 receptor in
monocytes and macrophages, following its endocytosis and degradation inside the macrophages.
If the hemolysis rate is high and haptoglobin is saturated, hemoglobin is degraded into heme, and
the free heme groups bind to hemopexin and again the complex is recognized and phagocytosed by
macrophages via the low-density lipoprotein receptor related protein LRP/CD91 [95,96].
As discussed earlier, ferrous iron may be drawn back to the circulation thanks to FPN1 and, after
being oxidized by ceruloplasmin, join apo-Tf and enter the cycle again. Macrophage cytoplasmic
ferrous iron may also be stored in ferritin. After suffering a lysosomal partial digestion, ferritin may
lead to the formation of hemosiderin, an insoluble iron store primarily found in macrophages [95,96].
6.5. Iron Homeostasis Regulation
The antimicrobial hepcidin preprotein is produced in the liver as a product of the expression of
the HAMP gene. To achieve its functional conformation, hepcidin must undergo proteolytic cleavage
by the enzyme furin, leading to the production of the active peptide hormone composed by 25 amino
acids. Hepcidin effects tend towards the reduction of circulating iron levels acting at two levels. In cells
like macrophages or hepatocytes, hepcidin binds to ferroportin and leads to its internalization and
degradation, so that less ferrous iron is exported to circulation. In enterocytes, hepcidin seems to inhibit
DMT1 production transcriptionally, inducing a decrease in ferrous iron uptake in the duodenum [98,99].
Hepcidin levels are in turn controlled by numerous hepatic proteins. Hemojuvelin (HJV) is
a membrane protein with a pivotal role in the control of hepcidin expression. In the membrane,
HJV acts as a co-receptor and mediates the binding between the bone morphogenic protein receptor
(BMPR) and its substrate, the bone morphogenic protein (BMP). This complex leads to the subsequent
phosphorylation of cytosolic small-mothers-against-decapentaplegic proteins (SMADs). Then, a
complex of SMAD proteins enters the nucleus and activates the transcription of the HAMP gene
after binding to the BMP responsive element at its promoter. After being cleaved by matriptase-2,
HJV is converted into a soluble form that may act as an antagonist in the interaction BMP-BMPR,
inhibiting hepcidin expression [99–101]. The hemochromatosis protein (HFE) and both transferrin
receptors (TfR1 and TfR2) are also part of a hepcidin level regulatory pathway via the ERK/MAPK
pathway. With high plasma iron levels, as TfR1 presents a higher affinity for holo-Tf than for HFE, HFE
dissociates and binds to TfR2. Thereafter, the holo-Tf-HFE-TfR2 complex activates the ERK signaling
pathway, resulting in HAMP expression [99,101]. Erythropoiesis also inhibits hepcidin synthesis in
hepatocytes, because erythroid precursors release erythroferrone (ERFE), which suppress hepcidin
expression to facilitate iron acquisition for hemoglobin synthesis [102,103].
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As the reduction of iron levels limits the growth of iron-dependent micro-organisms, hepcidin
expression is a defensive mechanism after infection and inflammation. Increased levels of cytokines
such as IL-6 after infection lead to the activation of Janus kinases (JAK), which phosphorylate signal
transducers and activators of transcription (STAT) proteins. STAT3 can now enter the nucleus and
activate HAMP expression [99,104].
Another mechanism of iron homeostasis regulation is displayed by iron regulatory proteins (IRP)
and iron responsive elements (IRE). IREs are located in the untranslated region (UTR) of mRNAs that
encode iron metabolism proteins. If located in the 5’ UTR, after binding of the IRP, the IRE blocks the
translation of the encoded protein. On the other hand, when located in the 3’ UTR, the IRE mediates
the stabilization of the mRNA and thus facilitates translation [105].
Finally, hypoxia inducible factor (HIF) is crucial in adaptive responses to low oxygen levels and,
at the same time, is regulated by iron and regulates iron homeostasis. Under normal oxygen level
conditions, the alpha subunit of HIF is degraded by means of members of the prolyl hydroxylase
domain (PHD) family. As PHD activity depends on iron and oxygen levels, under low oxygen
conditions PHD activity decreases and HIF is not degraded. Here we discuss the role of the main
HIF isoforms involved in iron metabolism regulation, HIF-1 and HI-2. HIF-2 regulates erythropoiesis
by affecting erythropoietin hormone levels (EPO) and iron mobilization via the activation of the
transcription of DMT1, DcytB and FPN. HIF-2 also represses hepcidin production in the liver. On the
other hand, HIF-1 has been proven to regulate TfR1 and HO-1 expression, establishing a link between
iron metabolism and hypoxia [106].
Recently, research has focused in the role of microRNAs (miRNAs), small non-coding RNAs, in
the regulation of proteins involved in iron homeostasis at every level: iron uptake (TfR and DMT1),
iron export (FPN), iron storage (ferritin), iron regulation (HFE and HJV) and even iron utilization
(ISCU) [73]. In this line, miRNA122 has been found to act by silencing genes that control systemic iron
levels such as HFE, HV, BMPR1A or even HAMP. Moreover, iron overload reduces the expression of
miRNA122 [107].
7. Iron Metabolism in Obesity
Obesity has been found to influence every step of iron metabolism. Furthermore, the implication
of each of these steps in the pathophysiology of obesity-related anemia has been studied in animal
models, in adulthood obesity and in childhood obesity. In the next paragraphs we summarize the
published evidence on this relationship between obesity and iron metabolism from a molecular and
mechanistic point of view (Table 1). The described changes are summarized in Figure 3.
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Figure 3. Iron metabolism dysregulation in obesity. Obesity influences iron metabolism at many steps of the cycle. No alterations have been proven in iron ingested 
from the diet (A), nor in its reduction from Fe3+ to Fe2+ in the stomach (B). In the duodenum enterocytes in obese patients, DMT1 density increases at the apical 
membrane, whereas ZIP14 and 8 co transporters decrease. HO1 levels increase intracellularly and at the basal membrane CP and FLVCR increase, whereas FPN1, 
BCRP and HEPH decrease (C). Ferritin circulating levels increase (D). Myocyte and hepatocyte transferrin receptor density increases, together with an increase in 
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Figure 3. Iron metabolism dysregulation in obesity. Obesity influences iron metabolism at many steps of the cycle. No alterations have been proven in iron ingested
from the diet (A), nor in its reduction from Fe3+ to Fe2+ in the stomach (B). In the duodenum enterocytes in obese patients, DMT1 density increases at the apical
membrane, whereas ZIP14 and 8 co transporters decrease. HO1 levels increase intracellularly and at the basal membrane CP and FLVCR increase, whereas FPN1,
BCRP and HEPH decrease (C). Ferritin circulating levels increase (D). Myocyte and hepatocyte transferrin receptor density increases, together with an increase in
DMT1 and a decrease in ZIP14 (E,F). Additionally, in hepatocytes, NCOA4 decreases, preventing ferritin degradation, and HEPH and FPN1 decrease, reducing the Fe2+
sent to circulation (F). Decreased levels of transferrin receptors are found in proerythroblasts (G). Changes in macrophages recycling Fe2+ from hemoglobin include an
increase in hemopexin, Hp and CD163, indicating an increase in the capacity to uptake heme groups and hemoglobin, and an increase in CP with a decrease in FPN1,
suggesting a decrease in the Fe2+ liberated to circulation, but an increased oxidizing capacity to Fe3+ (H). Finally, no changes in daily iron loss has been described (I).
Vit. C: vitamin C; DMT1: divalent metal transporter 1; ZIP 14/8: Zrt–Irt-like protein 14 and 8; DcytB: duodenal cytochrome B; STEAP 2: six-transmembrane epithelial
antigen of the prostate 2; HCP1: heme carrier protein 1; AP2: adaptor-related 2 protein; PCBP: poly (rC) binding protein; LIP: labile iron pool; HO1: heme oxygenase 1;
FPN1: ferroportin 1; HEPH: hephaestin; CP: ceruloplasmin; FLVCR: feline leukemia virus subgroup C; BCRP: breast cancer-resistant protein; Tf: transferrin; TfR:
transferrin receptor; CAT: catalase; Scara 5: scavenger receptor class A, member 5; TIM2: T-cell immunoglobulin and mucin domain-containing protein 2; STEAP
3: six-transmembrane epithelial antigen of the prostate 3; NCOA4: nuclear receptor coactivator 4; BFU-e: burst forming unit-erythroid; CFU-e: colony forming
unit-erythroid; EPO: erythropoietin; Hb: hemoglobin; Hp: haptoglobin; CD163: cluster of differentiation 163; CD91/LRP: cluster of differentiation/ low-density
lipoprotein receptor related protein; HRG: heme responsive gene. Upregulated transporters and enzymes are shown with a green arrow pointing upwards, whereas
downregulated transporters and enzymes are shown with a red arrow pointing down.
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7.1. Iron Absorption
A study including metabolically healthy and insulin-resistant obese adults found HO-1 levels
to be a positive predictor of metabolic disease in humans. Moreover, depletion of HO-1 in mice
protects the animal from developing insulin resistance and inflammation related with obesity [108].
In accordance with these results, obese children in Mexico have been found to have increased HO-1
levels [109]. Nonetheless, after treating cultured adipocytes and macrophages with hemin (HO-1
inductor), macrophages experience a switch to their anti-inflammatory phenotype, acting as a defense
against obesity-induced inflammation and insulin resistance [110]. Likewise, when an animal model
of obesity (mice receiving a high fat diet, HFD) is treated with an HO-1 inducer, it results in improved
endothelial cell function and repressed adipogenesis [111].
In obese individuals, a loss of JAK3 mediated phosphorylation of BCRP leads to intestinal
dysfunction of this heme transporter [112]. FLVCR1 mRNA expression is positively correlated with
fasting glucose and negatively correlated with insulin sensitivity, but no significant changes were
observed related to weight gain in HFD-induced obese mice [113].
Although hepcidin implication in obesity-related iron deficiency will be later discussed, Sonnweber
et al. described this situation to be derived from impaired ferrous iron absorption in the duodenum.
They found Dcytb and hephaestatin oxidoreductase mRNA levels to be lower in HFD-induced obese
mice, but found higher levels of TfR1 and DMT1 mRNA and proteins. Iron supplementation reversed
the increased TfR1 and DMT1 protein/mRNA levels [114].
After consumption of an HFD for 12 weeks, obese rats exhibited a reduction in the renal expression
of the anion exchanger NHE3 [115].
Zinc transporter expression has also been related to obesity in a group of obese Korean women.
mRNA levels of many zinc transporters such as ZnT4, ZnT5, ZnT9, ZIPp1, ZIP4 and ZIP6 were
significantly lower in obese women [116]. Related to that fact, plasmatic and erythroid zinc levels
appeared to be significantly lower in obese children when compared to a control group, and urinary
zinc secretion appeared higher, which may have some effect on insulin sensitivity, since zinc is involved
in insulin secretion and action [117,118].
7.2. Iron Storage
Rodent models lacking the active ferritin subunit (H-Ft) are unable to develop HFD-induced
obesity, as the reduction of intracellular iron deposits ameliorates the inflammatory state [119]. In a
study on the association of metabolic health in obesity and iron status markers in prepubescent
children, Suárez-Ortegón et al. found circulating ferritin levels to be related to metabolically unhealthy
obesity [120].
7.3. Iron Transport and Utilization
As mentioned above, HFD-induced obese mice present lower hephaestatin mRNA levels [114].
However, adipose tissue from obese humans (both adults and children) seems to contribute to higher
circulating CP levels [121–123]. Additionally, livers of HFD-induced obese mice presented lower iron
levels and increased endoplasmic reticulum stress (ERS), together with an impaired expression of
NCOA4 and ferritin [124].
Low concentrations of serum sTfR are indicators of a healthy tissue iron status. In accordance with
this, circulating levels of sTfR showed a direct correlation with BMI in 75 hyperferritinemic men [125].
Moreover, elevated sTfR serum levels served as a predictor of a higher risk of developing T2DM in
obese individuals [126].
On the other hand, Moreno-Navarrete et al. found circulating lactoferrin concentration to be
inversely associated with body mass index in adult men (BMI) [127]. Moreover, the same group also
found circulating lactoferrin to be negatively associated with hyperglycemia, inflammatory markers
and obesity, and directly associated with insulin sensitivity [128].
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LCN2 mRNA and protein levels were higher in obese patients when compared with lean subjects.
This increased expression was associated with increased inflammatory markers [129]. Moreover, LCN2
seems to play obesogenic and anti-thermogenic effects. These effects seem to be via the inhibition
of BAT activity, since after feeding wild-type and LCN2 knockout mice with HFD the second group
exhibited a lower weight gain and higher BAT activity [130]. However, LCN2 behavior in children
seems to be the opposite of that described in adults and in animals, since LCN2 plasmatic levels were
found to be decreased in 80 obese girls [131]. Megalin has been shown to play a protective role against
HFD-induced obesity in endothelial megalin-deficient mice [132] but data on humans have not been
yet published, to the best of our knowledge.
Deletion of FXN in mice leads to an impaired oxidative metabolism accompanied by a higher
predisposition of these animals to suffer from high-caloric diet-induced obesity [133], but again, to
date, this has not been explored in human obesity.
7.4. Iron Recycling
Serum haptoglobin levels were directly related to BMI, HOMA-IR, fasting insulin and blood
glucose levels in a group of obese women, and serve as a marker of obesity [134,135]. One possible
mechanism for such increased haptoglobin production in obesity is a TNFα-mediated induction, since
mice overexpressing TNFα present higher levels of haptoglobin and obese mice lacking this cytokine in
white adipose tissue (WAT) resulted in a downregulation of adipose haptoglobin [136]. More recently,
in Mexican adults and children, haptoglobin levels were found to be positively associated with obesity.
In the same study, the authors found the HP rs2000999 G allele to be related to haptoglobin levels, but
not obesity [137]. Moreover, the haptoglobin phenotype has been related to oxidative stress in obesity,
since the presence of the Hp 2 allele seems to be associated to lower levels of reduced glutathione
(tGSH) in obese children. This difference is even higher if the Hp phenotype is accompanied by
H63D polymorphism in the HFE gene [138]. CD163 expression is also elevated in obese subjects and
positively correlates with insulin resistance, as measured by HOMA-IR [139]. Obese children also
present higher CD163 levels, associated with markers of liver injury and with metabolic parameters.
Treating these children with changes in lifestyle resulted in changes in CD163, associated with, among
others, improvement of insulin sensitivity [140].
It is known that hemopexin mRNA levels are increased in inflammatory states, since cytokines such
as IL6 or TNFα induce its expression. However, insulin is able to attenuate this overexpression [141].
In adipocyte cell cultures, hemopexin increases with adipogenesis and if hemopexin expression is
truncated, adipocyte differentiation is impaired. In humans, hemopexin expression varies according to
the metabolic disease status, and serum hemopexin is related to triglyceride levels [142]. Concerning
its receptor, exome sequencing of the LRP1B gene in a cohort of children suffering from severe obesity
revealed a single nucleotide polymorphism (SNP), rs431809, in intron 4 to be significantly related to
BMI. Epigenetic modifications in this same intron were also found to be associated with BMI [143].
Obesity leads to a reduction in the iron content of adipose tissue infiltrated macrophages,
together with a reduction in the expression of some iron importers, and the level of the main iron
exporter, FPN1, was also found to be decreased in the liver of HFD-induced obese mice. Rats with
fatty diet induced-obesity present hemosiderin deposits and macrophages filled with hemosiderin
droplets [144,145].
7.5. Iron Homeostasis Regulation
A prospective analysis in a Chinese cohort has shown a relation between furin levels and the risk
of developing abdominal obesity. A population of 892 Chinese adults without abdominal obesity at
baseline was followed-up for four years. They found baseline serum furin deficiency to be a contributor
to abdominal obesity [146]. Gajewska et al. determined the iron status in a group of 80 children and
found the obese ones to have a 40% increase in hepcidin levels, as well as a 30% reduction in FPN1
levels. However, soluble transferrin receptor (sTfR), ferritin, iron or hemoglobin levels were similar,
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as well as the mean corpuscular volume (MCV), a sign of an iron deficiency-independent alteration
of the FPN-hepcidin axis [147]. In accordance, Park et al. found HAMP mRNA to be lower in an
HFD-induced murine model of obesity [148].
HJV mRNA expression has been found to be increased in obese patients’ adipose tissue, along with
hepcidin mRNA. This results in increased blood soluble HJV [149]. As reviewed by Blázquez-Medela
et al., many BMP isoforms are related to obesity and its comorbidities. Higher levels of BMP2 have
been described in WAT of overweight and obese individuals when compared to controls. In mice,
deletion of BMP4 results in reduced insulin sensitivity and increased adiposity. In animal models of
obesity, treatment with intraperitoneal injections of BMP7 resulted in body weight and inflammation
reduction. Other BMP isoforms such as BMP8B, BMP3 or BMP3B have also been related to obesity [150].
When analyzing BMPR1A expression in 297 subjects, Böttcher et al. found a direct relationship between
mRNA levels in adipose tissue and obesity. They also described single nucleotide polymorphisms
(SNPs) likely to be involved in this increased BMPR1A expression [151]. Additionally, HJV repressor
matriptase-2 deficient mice are protected from HFD-induced obesity, showing decreased BMI and
improved glucose tolerance and insulin sensitivity [152]. Thus, every component involved in the main
regulatory pathway controlling hepcidin synthesis is exacerbated in obesity, including the enzyme
involved in the cleavage of the active form (furin). To study the implication of SMAD proteins
in obesity-related metabolism, Seong et al. developed HFD-induced obese mice overexpressing
SMAD isoforms. They found SMAD2, 3 and 4 to improve obesity-related metabolic parameters and
inflammation; however, SMAD7 had detrimental effects by regulating MPK38 activity [153].
EPO supplementation in rodent models of obesity decreases body weight gain and glycated
hemoglobin levels (HbA1c) [154]. When the expression of the erythropoietin receptor (EPOR) is
restricted to hematopoietic tissues and absent in other tissues, mice develop obesity and insulin
resistance, together with a lower energy expenditure and greater white fat mass [155]. On the contrary,
cells treated with an EPO-derived peptide without erythroid activity but retaining other functions
suppress adipogenesis and ameliorate macrophage inflammatory activation. In HFD-induced obese
mice these peptides improved obesity and insulin resistance [156], pointing out that the obesogenic
and insulin-resistant effect of EPO is intimately related to its hematopoietic effect.
Although increased levels of cytokines such as IL6 are expected to increase hepcidin production
via the JAK-STAT pathway, adipose tissue STAT3 mRNA levels have been described to be lower in
HFD-induced obese rats and in obese children with hypertriglyceridemia [157]. Even so, in obesity,
chronic activation of JAK-STAT3 leads to leptin and insulin resistance in the central nervous system
and peripheral organs, respectively [158].
Soluble factors released from obese adipocytes lead to liver HIF1α overexpression and deletion of
hepatic HIF1α protection from obesity-induced glucose intolerance, without altering BMI or insulin
resistance in murine models [159]. The overexpression of the HIF1 alpha subunit leads to obesity by
inhibiting thermogenesis and cellular metabolism in brown adipose tissue (BAT) [160]. This remains
controversial, since inhibition of PHD in a murine model of obesity results in the stabilization of HIF1α
and, as a consequence, in a reduction of BMI and HDL-col level, as well as the improvement of some
obesity-related alterations such as macrophage infiltration into WAT or adipocyte fibrosis [161]. On the
other hand, the HIF2 isoform is proposed to have the opposite effect on obesity and its complications
than HIF1. Thus, HIF-2α knockout in mice worsens HFD-induced obesity and insulin resistance [162].
miRNAs involved in inflammation and iron metabolism have also been studied in obesity. A study
in 2018 found miRNA 155 (related to inflammation) and miRNA 122 (related to iron metabolism) to be
increased at both systemic and sperm levels in obese men [163].
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Table 1. Iron metabolism disturbances described in obesity.
Iron Metabolism
Level Protein Experimental Procedure Result Reference
Iron absorption
HO-1
Mice Ho-1 depletion IR and inflammation [108]
Quantification in




sensitivity, repressed adipogenesis [110,111]
BCRP Obese humans Intestinal dysfunction of thetransporter [112]
FLVCR1 Quantification in HFDmice
mRNA levels positive relation with
fasting glucose and negative with
insulin resistance
[113]
Dcytb Quantification in HFDmice Lower mRNA levels [114]
Hephaestatin Quantification in HFDmice Lower mRNA levels [114]
TfR1 Quantification in HFDmice Higher mRNA and protein levels [114]
DMT1 Quantification in HFDmice Higher mRNA and protein levels [114]
NHE3 Quantification in HFDmice Reduced renal expression [115]
Zinc transporters Obese women Reduced mRNA levels [116]
Iron storage Ferritin
H-Ferritin deletion in
HFD mice Anti-obesogenic state [119]





mice Decreased levels of FPN1 [144,145]
Quantification in HFD
mice
Decreased levels of FPN1 in obese
children [147]
Hephaestatin Quantification in HFDmice Lower mRNA levels [114]
CP Obese adults andchildren Higher circulating CP levels [121–123]
NCOA4 Quantification in HFDmice Impaired expression [124]
sTfR Obese humans Related to BMI in hyperferritinemia [125]
Lactoferrin Obese humans Inversely related to BMI and obesity [127,128]
LCN2
Obese humans Increased levels [129]
LCN2 knockout mice Obesogenic and anti-thermogenicactivity [130]
Obese children Decreased levels [131]
Megalin Endothelialmegalin-deficient mice
Protective role against HFD-induced
obesity [132]
Frataxin Frataxin deletion in mice
Impaired oxidative metabolism and
higher predisposition to suffer from
high-caloric diet-induced obesity
[133]
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Table 1. Cont.
Iron Metabolism
Level Protein Experimental Procedure Result Reference
Iron recycling
Haptoglobin
Obese women Relation with BMI, HOMA-IR, fastinginsulin or blood glucose blood levels [134,135]
Obese adults and
children
Positive association with obesity and
allele related to haptoglobin levels [137]
Obese children Allele related to oxidative stress inobesity [138]
CD163




Changes in CD163 associated with




Higher mRNA levels in inflammatory





Variations according to metabolic
disease status and triglyceride levels [142]
LRP Obese children SNPs and epigenetic modificationsrelated to BMI [143]
Iron homeostasis
regulation
Furin Obese humans Furin deficiency related to obesity risk [146]
Hepcidin Obese children Increased levels [147]
HJV Obese humans Increased mRNA levels in adiposetissue [149]
BMP 2 Obese humans Higher levels [150]
BMP 4 BMP4 deletion in mice Obesogenic effects [150]
BMP 7 HFD mice treated withBMP 7
Anti-obesogenic and
anti-inflammatory effects [150]
BMPR1A Obese humans Increased mRNA levels and SNPsinvolved [151]
Matriptase-2 Deficient matriptase-2mice






SMAD 2, 3 and 4 improve
obesity-related metabolic parameters
and inflammation. SMAD7 has
detrimental effects by regulating
MPK38 activity
[153]
EPO Mice Anti-obesogenic effects [154–156]
STAT3 Obese children and HFDmice Lower mRNA levels [157]
HIF1 Mice Obesogenic effects [159,160]
HIF1 Mice Anti-obesogenic effects [161]
HIF2 Mice Anti-obesogenic effects [162]
miRNA122 Obese humans Increased levels [163]
8. Concluding Remarks
In the last decades, obesity, and in particular childhood obesity, has become a worldwide pandemic,
affecting a third of preschool children in developing countries. Both inflammatory and oxidative states
have been related to the development of obesity-associated complications. As pediatric obesity increases
the risk of developing several comorbidities in both childhood and adulthood, it has become crucial to
gather the existing knowledge on the molecular and cellular alterations found in these conditions. Iron
deficiency, the most common nutritional disorder in the world, is one of the comorbidities associated
with obesity, and although some hypotheses have been suggested, the underlying mechanisms for
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obesity-associated iron deficiency and anemia remain unclear. Recent evidence shows that iron
metabolism alteration might not just be a consequence of obesity, but may play a pivotal role in the
development of obesity metabolic derangements.
In this review we attempted to provide an overview of the molecular and cellular perturbations
found in obesity and metabolic syndrome related to iron homeostasis and regulation, and how these
interact with each other. Specifically, we have revised the evidence of the alterations found in iron
absorption, storage, transport, utilization, recycling and homeostasis regulation. We describe how
these relate to inflammation and oxidative stress in obesity.
9. Future Directions
The complexity of obesity-related iron metabolism alterations reviewed in this work illustrates the
need for further research to accomplish future preventive and therapeutic interventions. Less is known
on the role of OS in iron metabolism disturbances and its effects at the cellular level. As previously
described by our group, metabolic derangements in obese children are related, at least, to higher
levels of lipid oxidation markers and a deficient capacity of those children to activate their antioxidant
defenses. This increased OS could lead to metabolic dysregulation at several levels and even to cellular
damage and destruction of erythrocytes. The question of whether reestablishing iron homeostasis may
improve metabolic, inflammatory and OS states could open a completely innovative approach in the
treatment of obesity metabolic comorbidities, and remains to be tested.
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45. Mărginean, C.O.; Meliţ, L.E.; Ghiga, D.V.; Mărginean, M.O. Early Inflammatory Status Related to Pediatric
Obesity. Front. Pediatr. 2019, 7, 241. [CrossRef] [PubMed]
46. Hussain, T.; Tan, B.; Yin, Y.; Blachier, F.; Tossou, M.C.B.; Rahu, N. Oxidative Stress and Inflammation: What
Polyphenols Can Do for Us? Oxidative Med. Cell. Longev. 2016, 2016, 1–9. [CrossRef]
47. Biswas, S.K. Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant
Paradox? Oxidative Med. Cell. Longev. 2016, 2016, 17–19. [CrossRef]
48. Avelar, T.M.T.; Storch, A.S.; Castro, L.A.; Azevedo, G.V.M.M.; Ferraz, L.; Lopes, P.F. Oxidative stress in the
pathophysiology of metabolic syndrome: Which mechanisms are involved? J. Bras. Patol. Med. Lab. 2015, 51,
231–239. [CrossRef]
49. Lechuga-Sancho, A.M.; Gallego-Andujar, D.; Ruiz-Ocaña, P.; Visiedo, F.M.; Saez-Benito, A.; Schwarz, M.;
Segundo, C.; Mateos, R.M. Obesity induced alterations in redox homeostasis and oxidative stress are present
from an early age. PLoS ONE 2018, 13, e191547. [CrossRef]
50. Kilic, E.; Özer, Ö.F.; Toprak, A.E.; Erman, H.; Torun, E.; Ayhan, S.K.; Caglar, H.G.; Selek, S.; Kocyigit, A.
Oxidative Stress Status in Childhood Obesity: A Potential Risk Predictor. Med. Sci. Monit. 2016, 22,
3673–3679. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 5529 22 of 27
51. Correia-Costa, L.; Sousa, T.; Morato, M.; Cosme, D.; Afonso, J.; Areias, J.C.; Schaefer, F.; Guerra, A.;
Afonso, A.C.; Azevedo, A.; et al. Oxidative stress and nitric oxide are increased in obese children and
correlate with cardiometabolic risk and renal function. Br. J. Nutr. 2016, 116, 805–815. [CrossRef]
52. Leo, F.; Rossodivita, A.; Segni, C.; Raimondo, S.; Canichella, S.; Silvestrini, A.; Miggiano, G.; Meucci, E.;
Mancini, A. Frailty of Obese Children: Evaluation of Plasma Antioxidant Capacity in Pediatric Obesity.
Exp. Clin. Endocrinol. Diabetes 2016, 124, 481–486. [CrossRef]
53. Stenzel, A.; Carvalho, R.; Jesus, P.; Bull, A.; Pereira, S.; Saboya, C.; Ramalho, A. Serum Antioxidant
Associations with Metabolic Characteristics in Metabolically Healthy and Unhealthy Adolescents with
Severe Obesity: An Observational Study. Nutrients 2018, 10, 150. [CrossRef] [PubMed]
54. Wenzel, B.; Stults, H.; Mayer, J. Hypoferræmia in Obese Adolescents. Lancet 1962, 280, 327–328. [CrossRef]
55. Menzie, C.M.; Yanoff, L.B.; Denkinger, B.I.; McHugh, T.; Sebring, N.G.; Calis, K.A.; Yanovski, J.A.
Obesity-Related Hypoferremia Is Not Explained by Differences in Reported Intake of Heme and Nonheme
Iron or Intake of Dietary Factors that Can Affect Iron Absorption. J. Am. Diet. Assoc. 2008, 108, 145–148.
[CrossRef] [PubMed]
56. Coimbra, S.; Catarino, C.; Santos-Silva, A. The role of adipocytes in the modulation of iron metabolism in
obesity. Obes. Rev. 2013, 14, 771–779. [CrossRef] [PubMed]
57. Schmidt, F.M.; Weschenfelder, J.; Sander, C.; Minkwitz, J.; Thormann, J.; Chittka, T.; Mergl, R.; Kirkby, K.C.;
Faßhauer, M.; Stumvoll, M.; et al. Inflammatory Cytokines in General and Central Obesity and Modulating
Effects of Physical Activity. PLoS ONE 2015, 10, e0121971. [CrossRef] [PubMed]
58. Ferrucci, L.; Guralnik, J.M.; Woodman, R.C.; Bandinelli, S.; Lauretani, F.; Corsi, A.M.; Chaves, P.H.M.;
Ershler, W.B.; Longo, D.L. Proinflammatory state and circulating erythropoietin in persons with and without
anemia. Am. J. Med. 2005, 118, 1288.e11–1288.e19. [CrossRef]
59. Zhao, L.; Zhang, X.; Shen, Y.; Fang, X.; Wang, Y.; Wang, F. Obesity and iron deficiency: A quantitative
meta-analysis. Obes. Rev. 2015, 16, 1081–1093. [CrossRef]
60. Manios, Y.; Moschonis, G.; Chrousos, G.P.; Lionis, C.; Mougios, V.; Kantilafti, M.; Tzotzola, V.; Skenderi, K.P.;
Petridou, A.; Tsalis, G.; et al. The double burden of obesity and iron deficiency on children and adolescents
in Greece: The Healthy Growth Study. J. Hum. Nutr. Diet. 2013, 26, 470–478. [CrossRef]
61. Del Giudice, E.M.; Santoro, N.; Amato, A.; Brienza, C.; Calabrò, P.; Wiegerinck, E.T.; Cirillo, G.; Tartaglione, N.;
Grandone, A.; Swinkels, D.W.; et al. Hepcidin in obese children as a potential mediator of the association
between obesity and iron deficiency. J. Clin. Endocrinol. Metab. 2009, 94, 5102–5107. [CrossRef]
62. Sal, E.; Yenicesu, I.; Celik, N.; Pasaoglu, H.; Celik, B.; Pasaoglu, O.T.; Kaya, Z.; Kocak, U.; Camurdan, O.;
Bideci, A.; et al. Relationship between obesity and iron deficiency anemia: Is there a role of hepcidin?
Hematology 2018, 23, 542–548. [CrossRef]
63. Aigner, E.; Feldman, A.; Datz, C. Obesity as an emerging risk factor for iron deficiency. Nutrients 2014, 6,
3587–3600. [CrossRef] [PubMed]
64. Bertinato, J.; Aroche, C.; Plouffe, L.J.; Lee, M.; Murtaza, Z.; Kenney, L.; Lavergne, C.; Aziz, A. Diet-induced
obese rats have higher iron requirements and are more vulnerable to iron deficiency. Eur. J. Nutr. 2014, 53,
885–895. [CrossRef] [PubMed]
65. Fujita, B.; Strodthoff, D.; Fritzenwanger, M.; Pfeil, A.; Ferrari, M.; Goebel, B.; Figulla, H.R.; Gerdes, N.; Jung, C.
Altered red blood cell distribution width in overweight adolescents and its association with markers of
inflammation. Pediatr. Obes. 2013, 8, 385–391. [CrossRef] [PubMed]
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